---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AAN | American Academy of Neurology |
| ACh | Acetylcholine |
| AChR | Acetylcholine receptor |
| ADA | Antidrug antibody |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| ALT | Alanine aminotransferase |
| ANA | Antinuclear antibody |
| AST | Aspartate aminotransferase |
| ATC | Anatomical Therapeutic Chemical |
| CH50 | Total hemolytic complement activity |
| CHO | Chinese hamster ovary |
| CI | Confidence interval |
| CIDP | Chronic inflammatory demyelinating polyneuropathy |
| CMAP | Compound muscle action potential |
| CPIO | Cost per improved outcome |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CTIS | Clinical Trials Information System |
| DIL | Drug-induced lupus |
| dsDNA | Double-stranded DNA |
| EAMG | Experimental autoimmune myasthenia gravis |
| EMG | Electromyography |
| EOMG | Early-onset myasthenia gravis |
| EQ-5D | EuroQol 5-dimension questionnaire |
| EQ-5D-5L | EuroQol 5-dimension, 5-level questionnaire |
| evLYG | Equal value of life-years gained |
| FACIT | Functional Assessment of Chronic Illness Therapy |
| FcRn | Neonatal Fc receptor |
| FDA | U.S. Food and Drug Administration |
| FFS | Fee-for-service |
| FSS | Fatigue Severity Scale |
| GC | Glucocorticoid |
| gMG | Generalized myasthenia gravis |
| HBPB | Health benefit price benchmark |
| HCRU | Healthcare resource utilization |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| HUI3 | Health Utilities Index Mark 3 |
| IC90 | Concentration producing 90% inhibition |
| IC95 | Concentration producing 95% inhibition |
| ICER | Incremental cost-effectiveness ratio; Institute for Clinical and Economic Review |
| IgG | Immunoglobulin G |
| IND | Investigational New Drug application |
| INN | International nonproprietary name |
| IS | Immunosuppressant |
| ISR | Injection site reaction |
| IV | Intravenous |
| IVIg | Intravenous immunoglobulin |
| LOMG | Late-onset myasthenia gravis |
| LOS | Length of stay |
| LRP4 | Low-density lipoprotein receptor-related protein 4 |
| MAC | Membrane attack complex |
| MAD | Multiple ascending dose |
| MedDRA | Medical Dictionary for Regulatory Activities |
| MG | Myasthenia gravis |
| MG-ADL | Myasthenia Gravis Activities of Daily Living |
| MG-QoL-15r | Myasthenia Gravis Quality of Life 15-item revised |
| MGC | Myasthenia Gravis Composite |
| MGFA | Myasthenia Gravis Foundation of America |
| MGTX | Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone |
| MMN | Multifocal motor neuropathy |
| MMRM | Mixed model for repeated measures |
| MSE | Minimal symptom expression |
| MTX | Methotrexate |
| MuSK | Muscle-specific kinase |
| NHS | National Health Service |
| NMA | Network meta-analysis |
| NMJ | Neuromuscular junction |
| NMOSD | Neuromyelitis optica spectrum disorder |
| NNT | Number needed to treat |
| NSIST | Nonsteroidal immunosuppressive therapy |
| OLE | Open-label extension |
| OR | Odds ratio |
| PD | Pharmacodynamics |
| PIS | Postintervention status |
| PK | Pharmacokinetics |
| PLEX | Plasma exchange |
| PPPM | Per patient per month |
| PY | Person-years |
| Q2W | Every 2 weeks |
| Q4W | Every 4 weeks |
| QALY | Quality-adjusted life-year |
| QMG | Quantitative Myasthenia Gravis score |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| RNS | Repetitive nerve stimulation |
| RR | Rate ratio |
| SAD | Single ascending dose |
| SAE | Serious adverse event |
| SC | Subcutaneous |
| SCIg | Subcutaneous immunoglobulin |
| SD | Standard deviation |
| SFEMG | Single-fiber electromyography |
| SLE | Systemic lupus erythematosus |
| SLR | Systematic literature review |
| TEAE | Treatment-emergent adverse event |
| TPP | Target product profile |
| ULN | Upper limit of normal |
| WHO | World Health Organization |
| YTE | Tyrosine, threonine, and glutamate substitutions in the Fc domain that extend half-life |

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
